
- /
- Supported exchanges
- / F
Pulse Biosciences Inc (6L8 F) stock market data APIs
Pulse Biosciences Inc Financial Data Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pulse Biosciences Inc data using free add-ons & libraries
Get Pulse Biosciences Inc Fundamental Data
Pulse Biosciences Inc Fundamental data includes:
- Net Revenue: -9 000
- EBITDA: -47 334 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-09
- EPS/Forecast: -0.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pulse Biosciences Inc News

Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases
Key Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion The largest shareholder of the company is Robert Duggan with a 68% stake Insiders have...


Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
HAYWARD, Calif., January 02, 2024--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation ...

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif., December 20, 2023--(BUSINESS WIRE)--Pulse...

Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock
Pulse Biosciences, Inc. (NASDAQ:PLSE) shareholders (or potential shareholders) will be happy to see that the Executive Chairman, Robert Duggan, recently bought a whopping US$2.0m worth of stock, at a ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.